Aquestive Therapeutics, Inc. Costs and Expenses
Aquestive Therapeutics, Inc. (AQST) reported Costs and Expenses of $22.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-11
- Aquestive Therapeutics, Inc. costs and expenses for the quarter ending 2026-06-30 was $22.04M, a 3.14% increase year-over-year.
- Aquestive Therapeutics, Inc. costs and expenses for the quarter ending 2026-03-31 was $18.65M, a 33.59% decline year-over-year.
- Aquestive Therapeutics, Inc. costs and expenses for the quarter ending 2025-12-31 was $41.85M, a 64.48% increase year-over-year.
- Aquestive Therapeutics, Inc. costs and expenses for the quarter ending 2025-09-30 was $24.29M, a 11.24% increase year-over-year.
- Aquestive Therapeutics, Inc. costs and expenses for fiscal 2025 was $115.60M, a 30.87% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. costs and expenses for fiscal 2024 was $88.33M, a 34.48% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. costs and expenses for fiscal 2023 was $65.69M, a 26.81% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. costs and expenses for fiscal 2022 was $89.75M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.04M 10-Q · filed 2026-08-11 | $40.69M 10-Q · filed 2026-08-11 | $82.55M derived: sum of 3 quarters · filed 2026-08-11 | $106.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $18.65M 10-Q · filed 2026-05-13 | $60.50M derived: sum of 2 quarters · filed 2026-05-13 | $84.79M derived: sum of 3 quarters · filed 2026-05-13 | $106.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $41.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $66.14M derived: sum of 2 quarters · filed 2026-03-04 | $87.51M derived: sum of 3 quarters · filed 2026-08-11 | $115.60M 10-K · filed 2026-03-04 |
| 2025-09-30 | $24.29M 10-Q · filed 2025-11-05 | $45.66M derived: sum of 2 quarters · filed 2026-08-11 | $73.74M 10-Q · filed 2025-11-05 | $99.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $21.37M 10-Q · filed 2026-08-11 | $49.46M 10-Q · filed 2026-08-11 | $74.90M derived: sum of 3 quarters · filed 2026-08-11 | $96.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $28.09M 10-Q · filed 2026-05-13 | $53.53M derived: sum of 2 quarters · filed 2026-05-13 | $75.36M derived: sum of 3 quarters · filed 2026-05-13 | $95.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $25.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $47.28M derived: sum of 2 quarters · filed 2026-03-04 | $67.32M derived: sum of 3 quarters · filed 2026-03-04 | $88.33M 10-K · filed 2026-03-04 |
| 2024-09-30 | $21.83M 10-Q · filed 2025-11-05 | $41.88M derived: sum of 2 quarters · filed 2025-11-05 | $62.89M 10-Q · filed 2025-11-05 | $80.00M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $20.04M 10-Q · filed 2025-08-11 | $41.05M 10-Q · filed 2025-08-11 | $58.17M derived: sum of 3 quarters · filed 2025-08-11 | $73.55M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $21.01M 10-Q · filed 2025-05-12 | $38.13M derived: sum of 2 quarters · filed 2025-05-12 | $53.51M derived: sum of 3 quarters · filed 2025-05-12 | $70.96M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $17.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $32.50M derived: sum of 2 quarters · filed 2025-03-05 | $49.95M derived: sum of 3 quarters · filed 2025-03-05 | $65.69M 10-K · filed 2025-03-05 |
| 2023-09-30 | $15.38M 10-Q · filed 2024-11-04 | $32.83M derived: sum of 2 quarters · filed 2024-11-04 | $48.57M 10-Q · filed 2024-11-04 | $69.96M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $17.45M 10-Q · filed 2024-08-06 | $33.19M 10-Q · filed 2024-08-06 | $54.58M derived: sum of 3 quarters · filed 2024-08-06 | $74.90M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $15.74M 10-Q · filed 2024-05-07 | $37.13M derived: sum of 2 quarters · filed 2024-05-07 | $57.45M derived: sum of 3 quarters · filed 2024-05-07 | $83.48M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $21.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $41.71M derived: sum of 2 quarters · filed 2024-03-05 | $67.74M derived: sum of 3 quarters · filed 2024-03-05 | $89.75M 10-K · filed 2024-03-05 |
| 2022-09-30 | $20.32M 10-Q · filed 2023-11-06 | $46.34M derived: sum of 2 quarters · filed 2023-11-06 | $68.35M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $26.03M 10-Q · filed 2023-08-07 | $48.03M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $22.01M 10-Q · filed 2023-05-02 | |||
| 2021-09-30 | $21.25M 10-Q · filed 2022-11-01 | $43.12M derived: sum of 2 quarters · filed 2022-11-01 | $62.76M 10-Q · filed 2022-11-01 | $85.56M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $21.86M 10-Q · filed 2022-08-02 | $41.51M 10-Q · filed 2022-08-02 | $64.30M derived: sum of 3 quarters · filed 2022-08-02 | $86.34M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $19.65M 10-Q · filed 2022-05-04 | $42.44M derived: sum of 2 quarters · filed 2022-05-04 | $64.48M derived: sum of 3 quarters · filed 2022-05-04 | $85.76M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $22.80M 10-K · filed 2021-03-09 | $44.84M derived: sum of 2 quarters · filed 2021-11-02 | $66.12M derived: sum of 3 quarters · filed 2021-11-02 | $88.74M 10-K · filed 2021-03-09 |
| 2020-09-30 | $22.04M 10-Q · filed 2021-11-02 | $43.32M derived: sum of 2 quarters · filed 2021-11-02 | $65.95M 10-Q · filed 2021-11-02 | $92.27M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $21.28M 10-Q · filed 2021-08-03 | $43.91M 10-Q · filed 2021-08-03 | $70.23M derived: sum of 3 quarters · filed 2021-08-03 | $93.65M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $22.63M 10-Q · filed 2021-05-04 | $48.95M derived: sum of 2 quarters · filed 2021-05-04 | $72.37M derived: sum of 3 quarters · filed 2021-05-04 | $102.19M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $26.32M 10-K · filed 2021-03-09 | $49.74M derived: sum of 2 quarters · filed 2021-03-09 | $79.56M derived: sum of 3 quarters · filed 2021-03-09 | $105.28M 10-K · filed 2021-03-09 |
| 2019-09-30 | $23.42M 10-K · filed 2021-03-09 | $53.24M derived: sum of 2 quarters · filed 2021-03-09 | $78.95M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $29.82M 10-K · filed 2021-03-09 | $55.53M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $25.72M 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |